QQ客服 官方微博 反馈留言

浏览/检索结果: 共19条，第1-10条 帮助 限定条件 发表日期：2021     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases 期刊论文 MOLECULAR BRAIN, 2021, 卷号: 14 作者:  Xu, Yanjun;  Huang, Zhiyu;  Yu, Xiaoqing;  Chen, Kaiyan;  Fan, Yun 收藏  |  浏览/下载：74/0  |  提交时间：2022/01/25 Brain metastases  Predictive biomarker  DNA methylation  Somatic mutation  Advanced non-small cell lung cancer (advanced NSCLC)   Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China 期刊论文 THORACIC CANCER, 2021 作者:  Shi, Yuequan;  Fang, Jian;  Zhou, Chengzhi;  Liu, Anwen;  Wang, Yan 收藏  |  浏览/下载：65/0  |  提交时间：2022/01/25 advanced lung cancer  immune checkpoint inhibitors  immune-related adverse events  real-world data   LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang 收藏  |  浏览/下载：62/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study 期刊论文 CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021 作者:  Wang, Wenxian;  Gu, Xiaodong;  Wang, Liping;  Pu, Xingxiang;  Feng, Huijing 收藏  |  浏览/下载：29/0  |  提交时间：2022/01/10 Non-small cell lung cancer  PD-L1  Immune checkpoint inhibitor  Immune-related adverse event   Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy 期刊论文 ADVANCED HEALTHCARE MATERIALS, 2021, 页码: 25 作者:  Xu, Xiaoxuan;  Wu, Yao;  Qian, Xindi;  Wang, Yuqi;  Wang, Jiaoying 收藏  |  浏览/下载：43/0  |  提交时间：2021/12/16 cancer therapy  drug delivery  extracellular matrix  nanomedicine  tumor penetration   Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma 期刊论文 FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 卷号: 8 作者:  Fan, Ying;  Shan, Qianyun;  Gong, Jiali;  Qin, Jing;  Lu, Hongyang 收藏  |  浏览/下载：45/0  |  提交时间：2022/01/10 PPLELC  clinical characteristics  molecular characteristics  immunotherapy  PD-L1  TMB   Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer 期刊论文 TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 卷号: 10 作者:  Qiu, Bin;  Cai, Kaican;  Chen, Chun;  Chen, Jun;  Chen, Ke-Neng 收藏  |  浏览/下载：59/0  |  提交时间：2022/01/10 D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). 期刊论文 CANCER RESEARCH, 2021, 卷号: 81 作者:  Lu, Shun;  Zhang, Yiping;  Zhang, Guojun;  Zhou, Jianying;  Cang, Shundong 收藏  |  浏览/下载：59/0  |  提交时间：2021/11/01 The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer 期刊论文 TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10 作者:  Pan, Guoqiang;  Chen, Kaiyan;  Yu, Xiaoqing;  Sheng, Jiamin;  Fan, Yun 收藏  |  浏览/下载：38/0  |  提交时间：2021/11/01 Non-small cell lung cancer (NSCLC)  T790M abundance  droplet digital PCR (ddPCR)  next generation sequencing (NGS)  osimertinib   AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39 作者:  Socinski, Mark A.;  Spira, Alexander I.;  Paz-Ares, Luis G.;  Reck, Martin;  Lu, Shun 收藏  |  浏览/下载：32/0  |  提交时间：2022/01/10